Johnson & Johnson Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
Johnson & Johnson (JNJ) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $148.49 per share as of 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2026-02-11
- 2025-12-28: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $148.49.
- 2024-12-29: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $135.72.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $123.39.
- 2023-01-01: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $113.06.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2025-12-28 | $148.49 10-K · filed 2026-02-11 |
| 2024-12-29 | $135.72 10-K · filed 2025-02-13 |
| 2023-12-31 | $123.39 10-K · filed 2024-02-16 |
| 2023-01-01 | $113.06 10-K · filed 2023-02-16 |
| 2022-01-02 | $104.42 10-K · filed 2022-02-17 |
| 2021-01-03 | $96.97 10-K · filed 2021-02-22 |
| 2019-12-29 | $88.88 10-K · filed 2020-02-18 |
| 2018-12-30 | $82.03 10-K · filed 2019-02-20 |
| 2017-12-31 | $73.61 10-K · filed 2018-02-21 |
| 2017-01-01 | $65.77 10-K · filed 2017-02-27 |
| 2016-01-03 | $62.26 10-K · filed 2016-02-24 |
| 2014-12-28 | $61.94 10-K · filed 2015-02-24 |
| 2013-12-29 | $62.01 10-K · filed 2014-02-21 |
| 2012-12-30 | $61.15 10-K · filed 2013-02-22 |
| 2012-01-01 | $59.94 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |